Tools
Back to Results

Martin Beinborn, MD


Overview

Training + Education Duesseldorf University; Hannover Medical School; Harvard Medical School
Board Certifications Pharmacology, toxicology
Gender Male

Publications + National Presentations

Meng H, Krishnaji ST, Beinborn M, Kumar K. Influence of Selective Fluorination on the Biological Activity and Proteolytic Stability of Glucagon-like Peptide-1. Journal of Medicinal Chemistry 2008;51(22):7303-7307.

Murage EN, Schroeder JC, Beinborn M, Ahn JM. Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorganic & Medicinal Chemistry 2008;16(23):10106-10112.

Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS. Pharmacological Analysis of Human D1 and D2 Dopamine Receptor Missense Variants. Journal of Molecular Neuroscience 2008;34(3):211-223.

Liu G, Fortin JP, Beinborn M, Kopin AS. Four Missense Mutations in the Ghrelin Receptor Result in Distinct Pharmacological Abnormalities. Journal Pharmacology Experimental Therapeutics 2007;322(3):1036-1043.

Al-Fulaij MA, Ren Y, Beinborn M, Kopin A. Identification of Amino Acid Determinants of Dopamine 2 Receptor Synthetic Agonist Function. Journal of Pharmacology and Experimental Therapeutics 2007;321(1):298-307.

Beinborn M. Class B GPCRs: A hidden agonist within? Molecular Pharmacology 2006;70(1):1-4.

Mukherjee RS, McBride EW, Beinborn M, Dunlap K, Kopin AS. Point mutations in either subunit of the GABAB receptor confer constitutive activity to the heterodimer. Molecular Pharmacology 2006;70(4):1406-1413.

Masur K, Tibaduiza EC, Chen C, Ligon B, Beinborn M. Basal receptor activation by locally produced glucagon-like peptide-1 contributes to maintaining ß-cell function. Molecular Endocrinology 2005;19(5):1373-1382.

Beinborn M, Worrall CI, McBride EM, Kopin AS. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regulatory Peptides 2005;130(1-2):1-6.

Watanabe K, Beinborn M, Nagamatsu S, Ishida H, Takahashi S. Menetrier’s disease in a patient with helicobacter pylori infection is linked to elevated glucagons-like peptide-2 activity. Scandinavian Journal of Gastroenterology 2005;40(4):477-481.

Beinborn M, Ren Y, Bläker M, Chen C, Kopin AS. Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Molecular Pharmacology 2004;65(3):753-760.

Takabayashi T, Shimizu S, Clark BD, Beinborn M, Burke JF, Gelfand JA. Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells. Surgery 2004;135(5):544-554.

Doran AC, Wan Y-P, Kopin AS, Beinborn M. Established theory of radiation-induced decay is not generalizable to bolton-hunter labeled peptides. Biochemical Pharmacology 2003;65:1515-1520.

Kopin AS, McBride EW, Chen C, Freidinger RM, Chen D, Zhao C-M, Beinborn M. Identification of a series of CCK-2 receptor nonpeptide agonists: Sensitivity to stereochemistry and a receptor point mutation. Proceedings of the National Academy of Sciences, USA 2003;100(9):5525-5530.

Ren Y, Blaker M, Seshadri L, McBride EW, Beinborn M, Kopin AS. Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity. Journal of Molecular Neuroscience 2003;20:115-123.

Hearn MG, Ren Y, McBride EW, Reveillaud I, Beinborn M, Kopin AS. A drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants. Proceedings of the National Academy of Sciences, USA 2002;99(22):14554-14559.

Tibaduiza EC, Chen C, Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. Journal of Biological Chemistry 2001;276(41):37787-37793.

Foran SE, Carr DB, Lipkowski AW, Maszczynska I, Marchand JE, Misicka A, Beinborn M, Kopin AS, Kream RM. A substance P-opoid chimeric peptide as a unique nontolerance-forming analgesic. Proceedings of the National Academy of Sciences, USA 2000;97(13):7621-7626.

Kopin AS, McBride EW, Schaffer K, Beinborn M. CCK receptor polymorphisms: An illustration of emerging themes in pharmacogenomics. Trends in Pharmacol Sciences 2000;21(9):346-353.

Bläker M, Ren Y, Seshadri L, McBride EW, Beinborn M, Kopin AS. CCK-B/gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides. Molecular Pharmacology 2000;58:399-406.

Nagy L, Morales RE, Beinborn M, Vattay P, Szabo S. Investigation of gastroprotective compounds at subcellular level in isolated gastric mucosal cells. American Journal Physiol Gastrointes Liver Physiol 2000;279:G1201-G1208.

Foran SE, Carr DB, Lipkowski AW, Maszczynska I, Marchand JE, Misicka A, Beinborn M, Kopin AS, Kream RM. Inhibition of morphine tolerance development by a substance P-opiod peptide chimera. Journal of Pharmacology and Experimental Therapeutics 2000;295(3):1142-1148.

Kopin AS, Mathes WF, McBride EW, Nguyen M, Al-Haider W, Schmitz F, Bonner-Weir S, Kanarek R, Beinborn M. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. Journal of Clinical Investigation 1999;103(3):383-391.

Beinborn M, Chen C, DeMeo L, McBride EW, Kopin AS. Small synthetic ligands of the cholecystokinin-B/gastrin receptor can mimic the function of endogenous peptide hormones. Yale Journal of Biology and Medicine 1998;71:337-346.

Rindi G, Langhans N, Rehfeld JF, Beinborn M, Kopin AS. Abnormal gastric morphology and function in CCK-B/gastrin receptor-deficient mice. Yale Journal of Biology and Medicine 1998;71:347-354.

Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, Kopin AS. Mutations within the cholecystokinin-B/gastrin receptor ligand ‘pocket’ interconvert the functions of nonpeptide agonists and antagonists. Molecular Pharmacology 1998;54:857-863.

Schaffer K, McBride EW, Beinborn M, Kopin AS. Interspecies polymorphisms confer consitutive activity to the Mastomys cholecystokinin-B/gastrin receptor. Journal of Biological Chemistry 1998;273(44):28779-28784.

Beinborn M, Quinn SM, Kopin AS. Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. Journal of Biological Chemistry 1998;273(23):14146-14151.

Biography

Martin Beinborn is an Assistant Professor of Medicine at Tufts Medical Center and the Co-Director of the Molecular Pharmacology Research Center. He received his M.D. degree from Duesseldorf University, and went on to obtain postgraduate training in pharmacology at Hannover Medical School, Germany, as well as in molecular gastroenterology at Brigham and Women's Hospital / Harvard Medical School in Boston. In 1993, Dr. Beinborn was board-certified in the subspecialties of Pharmacology and Toxicology, and came to Tufts Medical Center to work with Dr. Alan Kopin on the molecular pharmacology of cholecystokinin/gastrin receptors. In addition to this ongoing collaboration, Dr. Beinborn has established a research program that focuses on the receptor for glucagon-like peptide, a potential target for the treatment of diabetes and obesity.

Contact Information

Phone: 617-636-7740

Email: MBeinborn@tuftsmedicalcenter.org

Molecular Cardiology Research Institute
Tufts Medical Center
800 Washington Street, Box #7703
Boston, MA 02111